In this video, we describe a method highlighting the utility of bioluminescence assay for sensitive and rapid screening of drugs. These drugs can be tested alone or in combination to assess the synergism in their mode of action.
Protocol
1. Bio-luminescence Based Measurement of Cell Viability
Coating plates with the extracellular matrix (ECM) mixture (e.g., Matrigel): Add 40 µL of 0.15 mg/mL ECM mixture to each well and incubate the plate for 1 h at 37 °C. Remove the excess ECM mixture and gently rinse once with PBS.
Add 100 µL culture medium containing 15,000, 10,000, 8,000, 6,000, 4,000, 2,000, 1,000, and 500 XG387-Luc cells together with 100 µL blank medium as control into each well for 6 replicates in a 96-well optical bottom plate and culture the cells overnight at 37 °C.
Remove the supernatant, add 50 µL culture medium containing 150 ng/µL D-luciferin into each well and incubate the cells for 5 min at 37 °C.
Take images of the cellular bio-luminescence in the plate using the IVIS spectrum imaging system. Use the built-in software to create multiple circular areas of the region of interest (ROI) and quantify the cellular bio-luminescence.
2. Temozolomide Treatment and Combination Screening
Precoat four 96-well plates as described above in step 1, prior to the treatment.
Seed XG387-Luc cells at a density of 1,000 cells in 100 µL culture medium into each well of a 96-well optical bottom plate and culture the cells overnight.
Prepare temozolomide and the targeted agents from the stock solution in advance. Prepare a concentration series composed of 800 µM, 600 µM, 400 µM, 300 µM, 200 µM, 100 µM, and 50 µM temozolomide in culture medium for the single-agent treatment. Dilute temozolomide and the targeted agents in stock solution in the culture medium, respectively, to obtain final concentrations of 200 µM and 2 µM for combination drug screening (Materials list).
Remove the culture medium when most of the GSCs adhere to the bottom of the plates; add the above-prepared medium containing temozolomide into each well for three technical replicates per treatment.
To treat Temozolomide and to screen the drug combinations remove the blank medium and add the above-prepared medium containing either 200 µM temozolomide, or 2 µM targeted agent, or a combination of both into each well for three technical replicates per treatment.
Incubate all plates at 37 °C, 5% CO2 for 3 days.
Remove the drug-containing medium, add 50 µL blank medium containing 150 ng/µL D-luciferin into each well and incubate the cells for 5 min at 37 °C.
Take images of the cellular bio-luminescence in the plate using the IVIS spectrum imaging system. Use the built-in software to create multiple circular ROIs and quantify the cellular bio-luminescence.
開示
The authors have nothing to disclose.
Materials
B-27
Gibco
17504-044
50X
EGF
Gibco
PHG0313
20 ng/ml
FGF
Gibco
PHG0263
20 ng/ml
Gluta Max
Gibco
35050061
100X
Neurobasal
Gibco
21103049
1X
Penicillin-Streptomycin
HyClone
SV30010
P: 10,000 units/ml S: 10,000 ug/ml
Sodium Pyruvate
Gibco
2088876
100 mM
ABT-737
MCE
Selective and BH3 mimetic Bcl-2 Bcl-xL and Bclw inhibitor
Adavosertib (MK-1775)
MCE
Wee1 inhibitor
Axitinib
MCE
Multi-targeted tyrosine kinase inhibitor
AZD5991
MCE
Mcl-1 inhibitor
A 83-01
MCE
Potent inhibitor of TGF-β type I receptor ALK5 kinase
CGP57380
Selleck
Potent MNK1 inhibitor
Dactolisib (BEZ235)
Selleck
Dual ATPcompetitive PI3K and mTOR inhibitor
Dasatinib
MCE
Dual Bcr-Abl and Src family tyrosine kinase inhibitor
Cellular Bioluminescence Based Assay: A High Throughput Method for Combinatorial Drug Screening. J. Vis. Exp. (Pending Publication), e20614, doi: (2023).